Current Studies


EMmY: Effectiveness and acceptability of myo-inositol nutritional supplement in the prevention of gestational diabetes: a pilot placebo controlled double blind randomised trial.


There has been an increase in Gestational Diabetes particularly among minority populations throughout the U.K. Gestational Diabetes has been linked to a number of Maternal and Fetal complications. In particular, it has been found that Women who have Gestational Diabetes will have a 70% increased risk of developing Type 2 diabetes with 10 years post-delivery. Further evidence suggests that Myo-Inositol has a promising role in preventing Gestational Diabetes by up to 60%. This is a nutritional supplement, shown to be safe during pregnancy.


In order to evaluate the effectiveness of administering myo-inositol to pregnant women to reduce the risk of gestational diabetes, the current study will ask the following main questions:


-What are the rates of recruitment and randomisation?

-What proportion of those randomised complete the study?

-What are the reasons for participation and non-participation?

Study Start: February 2018

Study Duration: 20 Months

Participating Sites:

-The Royal London Hospital

-Whipps Cross University Hospital 

-Newham University Hospital 

-St. George's Hospital

-Manchester Royal Infirmary 

Recruitment Target: 250  

Trial Contact Details:


Zoe Drymoussi, PhD
BARC Trial Coordinator
Barts Research Centre for Women’s Health
Women’s Health Research Unit | Queen Mary University of London
58 Turner Street | London E1 2AB

Tel: +4420 7882 6692 


Barts Centre for Women's Health Research 
Institute of Population Health Sciences
Barts and The London School of Medicine and Dentistry

Queen Mary University of London
Yvonne Carter Building
58 Turner Street
London E1 2AB

Tel: +44 (0)20 7882 2525

Contact Us